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Summary
Purpose: Most primary tumors spreading metastasis to the 
parotid gland are usually located in the head and neck re-
gion, nonetheless, rarely, parotid gland can also be the target 
of metastatic localization site of distant primary tumors. 
The purpose of this study was to describe a clinical series 
of metastasis to the parotid gland from distant primary tu-
mors (non Head & Neck).
Methods: The clinical databases of parotid tumors in two 
academic centers have been analyzed and 11 cases of pa-
rotid metastatic cancers from distant primary tumors were 
found.
Results: Primary tumor was lung cancer in 8 cases, and 
breast cancer, gastric carcinoma and pancreatic carcinoma 
in one case each.
Conclusions: Parotid metastases can be the first clinical 
manifestation of a malignant tumor from a distant site and 
can manifest years after curative-intent treatment of the dis-
tant primary. Histopathology and immunohistochemistry 
can help in the identification of the primary site. Parotidec-
tomy with complete excision of the parotid lesion may have 
diagnostic and/or loco-regional control and/or curative in-
tent, however there is still no international consensus about 
the therapy of parotid malignant metastasis.
Key words: distant primary, fine needle aspiration cytol-
ogy, malignant, metastasis, parotid, tumor
Introduction
 Metastases to the parotid gland are rare [1]. 
Most primary tumors spreading metastasis to the 
parotid gland are usually located in the head and 
neck, however parotid gland can also be the target 
of metastatic localization site of distant primary 
tumors. Even though this occurs rarely, clinician 
should always be aware of this possibility [2]. 
Cancers can spread to the parotid gland through 
the blood and lymphatic systems. So far there 
are only some case reports in the literature and 
very few series of metastases of distant primary 
tumors to the parotid gland. In particular, such 
metastases have been reported from breast can-
cer [3], renal cell carcinoma [4], small cell carci-
noma of the lung [5], melanoma [6], endometrium 
[7], gastrointestinal tract [7,8], liver [9], testicular 
seminoma [10], prostate and infraclavicular skin
[11-13].
 The purpose of this study was to present a 
clinical series of metastasis to the parotid gland 
from distant primary tumors, describing also the 
clinical features and their management.
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Methods
 Parotid tumors registered between January 1st 
1965 and December 31th 2015 in the databases of two 
academic centers (University Hospital of Ferrara and 
Padua) were retrospectively analyzed. A total of 11 cases 
of parotid metastatic cancers from distant primary tu-
mors have been identified. Patients with a primary Head 
and Neck cancer have been excluded from this study.
 For each identified case, the medical history, side, 
surgery, histology and origin of the primary cancer 
have been collected. Ultrasound, fine-needle aspiration 
cytology (FNAC), ultrasound-guided core biopsy, CT 
and MRI have been performed in most cases. 
 Staging prior to surgery included neck ultrasound 
examination, thyroid and salivary glands assessment 
in all patients. Contrast-enhanced CT scans or MRI 
have been performed in some cases.
 Surgical treatment options were incisional biopsy, 
superficial parotidectomy, total parotidectomy even 
with facial nerve sacrifice in one case.  
 Postoperative histopathological examination was 
performed in every case. Re-staging in relation to the 
primary tumor was then necessary, as it was clear that 
the nature of the parotid lesion was metastatic.
Results 
 Of the 11 diagnosed cases with parotid metas-
tasis, 7 were males and 4 females. The average age 
at  diagnosis was 66 years (range 55-85). The 11 
cases were divided in three subgroups: (i) the first 
in which parotid metastasis was the first clinical 
manifestation of an unknown primary distant tu-
mor; (ii) the second in which the parotid tumor was 
a metastatic localization of a known distant malig-
nant tumor (histopathology confirmed the meta-
static nature of the parotid lesion); (ii) the third 
group in which the parotid tumor represented re-
currence of a previously treated tumor (Table 1).
 The first group included 6 cases: 5 had pulmo-
nary primary carcinoma and 1 pancreatic adeno-
carcinoma. Within the 5 cases of lung cancer, case 
no.9 and case no.10 had a particular history. Case 
no. 9 had a previous history of non Hodgkin lym-
phoma that occurred 10 years ago, and was evalu-
ated due to the presence of neck nodes’ swelling 
and a parotid mass. The patient underwent a pa-
rotid biopsy and histology revealed lung carcino-
ma; no surgical intervention to the parotid gland 
was attempted due to the poor patient’s clinical 
condition. An atypical onset of disease was also 
present in case no.10: the patient developed a sud-
den parotid swelling, cytology revealed the pres-
ence of malignant cells and a total parotidectomy 
was performed: the final histological examination 
revealed a lung adenocarcinoma. In the other 4 
cases a total parotidectomy was performed owing 
to clinical and cytological suspicion of a parotid 
primary malignant tumor; however the final his-
tological examination revealed an origin different 
from the parotid.
 In the second group, there were 2 cases (no.6 
and no.11): both patients were treated for a lung 
cancer by radio and chemotherapy, however they 
developed a parotid swelling, and the cytological 
examination confirmed the presence of lung car-
cinoma metastasis in both cases. Case no. 6 was 
treated by total parotidectomy. Case no. 11 suf-
fered an uncontrolled metastatic lung carcinoma 
complicated also with cerebral metastases. 
 In the third group these were 3 cases. All 
these patients were previously treated for primary 
tumors, and the parotid lesions represented re-
currences of the previously treated tumors. In all 
cases there was no evidence of recurrence at the 
primary tumor site and the parotid lesions repre-
sented distant metastases. Metastases occurred 
Table 1. Patient demographics, histology and treatment data
Patient number Age (years)/Sex Site of primary tumor Histology Parotid management Group
1 58 F Lung SCLC TP 1
2 58 M Lung SCC TP 1
3 70 M Lung SCLC TP 1
4 63 M Pancreas Adenocarcinoma TP 1
5 55 F Breast Adenocarcinoma TP 3
6 82 M Lung Basaloid SCC TP 2
7 65 M Stomach Adenocarcinoma SP 3
8 73 F Lung Neuroendocrine TP + FN+ FND 3
9 52 M Lung Large cell carcinoma OB 1
10 75 F Lung Adenocarcinoma OB + TP 1
11 61 M Lung Adenocarcinoma FNAC 2
TP: total parotidectomy, FN: facial nerve sacrifice, OB: open biopsy, FND: functional neck dissection, M: male, F: female, SP: superifical 
parotidectomy, SCC: squamous cell carcinoma, SCLC: small cell lung cancer, FNAC: fine needle aspiration cytology
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after 12 months from the first tumor diagnosis in 
case no. 8,  after 18 months in case no. 7 and after 
16 months in case no. 5. Therefore, considering 
all the studied patients (Table 1), total parotidec-
tomy was performed in 8 cases with facial nerve 
sacrifice and functional neck dissection in one 
case. Case no.7 was treated with superficial parot-
idectomy. One case (no.9) underwent open biopsy 
alone as the clinical condition did not allow a total 
parotidectomy under general anesthesia. Finally, 
case no.11 underwent diagnostic cytology due to 
the presence of cerebral metastasis.
 The concordance between the preoperative 
FNAC and the final histology was of 63.6% (7 of 
11 patients).
 All patients died between 1 and 23 months 
from the diagnosis of metastatic disease; no spe-
cific statistical analysis was performed for overall 
survival, due to the histological heterogeneity of 
the group.
Discussion 
 Metastatic tumors to the parotid gland are 
uncommon. The vast majority of primary tumors 
giving metastases to the parotid gland are usually 
located in the head and neck region; metastatic lo-
calizations from distant primary tumors are even 
more rare.
 Primary tumors outside the head and neck 
region may give metastases to the parotid gland 
or its nodes (oncologically, there is no distinction 
between metastases located in the parotid paren-
chyma and metastases in parotid lymph nodes) [7] 
through the thoracic duct or the Batson’s paraspi-
nal venous plexus, bypassing pulmonary vascular 
filtration [14,15]. The route of haematogenous me-
tastasis is much less defined: Seifert et al. postulate 
that metastases in the parotid lymph nodes may 
be an expression of lymphatic metastasis, whereas 
the diagnosis of a parenchymal metastasis is an 
indication for haematogenous metastasis [7].
 Clinically, parotid metastatic lesions often ap-
pear as soft swellings, without involving the skin 
or producing facial nerve palsy. The diagnostic 
work-up include echography, cyto/histo-patholog-
ic assessment, CT and MRI. In the last years, PET-
CT is also becoming a relevant tool in the study 
of metastatic disease and in the search of the pri-
mary site.
 In recent reports, the sensitivity of parotid 
FNAC in the diagnosis of malignancy has been re-
ported to be in the range of 54-92%, with specific-
ity in the range of 86-100%.  The false-negative 
rate ranges from 2 to 31% and the false-positive 
rate from 0 to 7% [16,17].
 A reported alternative to FNAC is ultrasound-
guided biopsy or an open biopsy [18]; these need 
local anaesthesia and a small skin incision com-
pared to FNAC. A needle (usually 18 or 20G) is 
deployed by means of a spring-loaded automated 
biopsy device to obtain a core of intact tissue.
 CT and MRI are used both as preoperative ex-
aminations and could be very helpful in evaluating 
and detecting the nature of a parotid mass. Param-
eters such as site and number of lesions, overall 
morphology, size, margins, extraglandular infiltra-
tive growth pattern, perineural spread, presence 
of cervical adenopathy, radiological enhancement 
of lesions, diffusion weighted sequences, all are 
able to increase the specificity up to 0.96 and the 
sensitivity up to 0.88 in the differential diagnosis 
between benign and malignant lesions [19].
 However, secondary metastatic localizations 
to the parotid gland are still often diagnosed by 
their histological features [2], as in our clinical 
series: 9 patients discovered their primary tumor 
only after the surgical procedure.
 There is no international consensus about the 
treatment of parotid metastasis so far, and the 
agreement of a standard consensus management 
of parotid metastasis is a difficult challenge due to 
the complexity of the variables that affect patient 
survival. Some authors suggest parotidectomy 
with negative margins and with preservation of 
the facial nerve when possible in single parotid 
metastasis.
 Shi et al. [20] for example, advocate even an 
ipsilateral neck dissection when the spread oc-
curred predominantly via the lymphatic sys-
tem, whereas, in cases of haematogenous spread 
from distant sites, neck dissection is thought to 
be unnecessary. Other authors consider that pa-
rotid surgery does not improve life expectancy, 
since the prognosis of such patients is poor with 
a 5-year survival rate of only 10% and the only 
place that parotid surgery could find is symptoms’ 
control [21].
 It has also been reported that in skin can-
cers (squamous cell carcinoma and melanoma), 
the presence of parotid and neck nodal metasta-
ses implies more aggressive disease with poorer 
prognosis. Surgical management of the parotid 
and eventually the neck nodes combined with ra-
diation therapy remains the mainstay for the lo-
cal (parotid) control, but without improvement of 
prognosis [15].
 In case of metastasis from lung cancers, treat-
ment of metastatic parotid lesions is advocated 
with the only aim of locoregional control. In par-
ticular, Bumpous et al. suggest a combination of 
surgery and adjuvant irradiation [6]; Jecker et al. 
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reported that radical parotid surgery had poor ef-
fect in improving the life expectancy and conclud-
ed that all the current therapeutic procedures are 
ineffective [21].
 In conclusion, there is still no international 
consensus about the therapy of parotid malignant 
metastasis, and the overall prognosis of this dis-
ease remains very poor.
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